ADC Therapeutics S.A.
NYSE:ADCTBiotechnology
-$0.02 today
- Market cap
- $192.71M
- Beta
- 1.77
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$0.89
Volume 1.17M
Average 1.68M
ADCT Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
ADC Therapeutics S.A.NYSE: ADCT
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $3.87M (cash outflow) rose 57.4% year over year, ahead of the -925.0% change in trailing-twelve-month accounts payables.
Context
- Accounts payables amounted to 11.1% of revenue in FY2025, up 7.6 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +57.4% holds above the trailing-twelve-month pace of -925.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (9.04M) USD
- Year-over-year change
- -467.1%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.04M) | -467.1% |
| FY2024 | 2024-12-31 | 2.46M | -22.4% |
| FY2023 | 2023-12-31 | 3.17M | +923.5% |
| FY2022 | 2022-12-31 | 310K | -95.4% |
| FY2021 | 2021-12-31 | 6.8M | — |
Accounts Payables vs competitors
How ADCT compares with its peers on the latest reported figures
- ADCT's LTM Mar 2026 accounts payables of $10.3M is the 3rd largest of the 10 companies compared; the peer median is $7K.
- Its year-over-year change of -925.0% is the lowest of 10, against a peer median of -69.6%.
- Accounts payables amounts to 13.0% of revenue for ADCT, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.43M | -795.9% | — | 22.2% | |
| LTM Mar 2026 | $10.54M | +15832.8% | — | 11.9% | |
| LTM Mar 2026 | $10.3M | -925.0% | — | 13.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $4M | +845.6% | — | — |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $2.18M | +391.0% | — | 29.5% |
| LTM Mar 2026 | $1.74M | -181.3% | +289.5% | 1.9% | |
| LTM Mar 2026 | $1.2M | -69.6% | — | 1.9% | |
| LTM Mar 2026 | $979K | -84.6% | — | 9.9% | |
| LTM Mar 2026 | $665K | +135.3% | — | 4.5% | |
| LTM Mar 2026 | $7K | -100.7% | — | 0.4% | |
| Peer median (excluding ADCT) | $7K | -69.6% | +289.5% | 7.2% | |
Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (230.03M) | (157.13M) | (240.05M) | (157.85M) | (142.62M) |
| Depreciation & Amortization | 2.63M | 5.74M | 3.27M | 3.28M | 1.88M |
| Deferred Income Tax | (26.05M) | 0 | 37.1M | 0 | 0 |
| Stock-Based Compensation | 60.48M | 50.64M | 13.5M | 6.57M | 6.91M |
| Change in Working Capital | (15.71M) | (49.04M) | 44.27M | 3.83M | (25.36M) |
| Accounts Receivables | (30.22M) | (42.75M) | 47.79M | 4.77M | (8.79M) |
| Inventory | (3.02M) | (9.65M) | (5.71M) | (3.73M) | (2.38M) |
| Accounts Payables | 6.8M | 310K | 3.17M | 2.46M | (9.04M) |
| Other Working Capital | 10.73M | 3.37M | (979K) | 321K | (5.15M) |
| Other Non-Cash Items | (24.7M) | 11.48M | 23.23M | 20.34M | 18.02M |
| Operating Cash Flow | (233.38M) | (138.31M) | (118.69M) | (123.84M) | (141.17M) |
| Capital Expenditures | (6.38M) | (687K) | (3.22M) | (867K) | (264K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 659K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (3.24M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (6.67M) | (687K) | (3.22M) | (867K) | 395K |
| Debt Repayment | 48.61M | (2.71M) | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 60.51M | 152.46M |
| Common Stock Repurchased | 0 | (1.32M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 218.78M | 3.13M | 73.88M | 36.55M | (1.51M) |
| Financing Cash Flow | 267.39M | (897K) | 73.88M | 97.05M | 150.95M |
| Effect of Forex Changes | 6K | (208K) | 184K | (83K) | 305K |
| Net Change in Cash | 27.35M | (140.1M) | (47.84M) | (27.73M) | 10.47M |
| Free Cash Flow | (239.75M) | (139M) | (121.9M) | (124.7M) | (141.44M) |
ADC Therapeutics S.A.
NYSE:ADCT
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.